Frontiers in pharmacology · 2026
Effects of hydromorphone for patient-controlled intravenous analgesia on postpartum depression and sleep disorders after cesarean section: a randomized, double-blind controlled trial.
Клиническое исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhu Yun, Wang Chao, Chen Xiangxiang, Zhao Yuanyuan, Yang Lei, Wang Qi, Lv Jie, Wang Wei
Аннотация
BACKGROUND: Postpartum depression (PPD) is a significant concern in obstetrics. This study aimed to investigate the effects of hydromorphone in patient-controlled intravenous analgesia (PCIA) on PPD and sleep disorders following cesarean section.
METHODS: A total of 140 parturients undergoing elective cesarean section under combined spinal-epidural anesthesia, with singleton full-term pregnancy and aged 22-35 years, were enrolled from July to December 2025 at Jiangning Hospital Affiliated to Nanjing Medical University. Using a random number table, participants were allocated to two groups based on PCIA formulation: the sufentanil group (Group S) received sufentanil (3 μg/kg) + tropisetron (0.1 mg/kg) diluted to 150 mL with normal saline; the hydromorphone group (Group H) received hydromorphone (0.15 mg/kg) + tropisetron (0.1 mg/kg) diluted to 150 mL with normal saline. The primary outcome was the incidence of PPD at 6 weeks postoperatively. Secondary outcomes included PPD incidence at 1 week, Ramsay sedation scores at 24 and 48 h, Pittsburgh Sleep Quality Index (PSQI) scores preoperatively and at 24/48 h, resting Visual Analog Scale (VAS) pain scores at 6, 12, 24, and 48 h, PCIA button presses and rescue analgesia within 48 h, cumulative 48-hour opioid consumption, bowel function recovery time, first lactation time, neonatal behavioral neurological assessment (NBNA) scores at 48 h postoperatively and adverse reactions.
RESULTS: The incidence of PPD at 6 weeks was significantly lower in Group H compared to Group S [5.8% vs. 20.6%, relative risk (RR) = 0.28, 95% confidence interval (CI) 0.10 to 0.78, P = 0.004]. The absolute risk reduction was 14.8% (95% CI 4.2%-25.4%), corresponding to a number needed to treat (NNT) of 7 (95% CI 4-24). Ramsay and PSQI scores at 24 and 48 h were also significantly lower in Group H (P < 0.01 for all), as was the incidence of dizziness and drowsiness within 48 h (P < 0.01). No significant intergroup differences were found in analgesia-related outcomes or other adverse reactions.
CONCLUSION: Hydromorphone for PCIA after cesarean section can reduce the incidence of PPD at 6 weeks, improve early postoperative sleep quality, and decrease dizziness and drowsiness.
CLINICAL TRIAL REGISTRATION: https://www.chictr.org.cn/bin/home, identifier ChiCTR2500105264.
METHODS: A total of 140 parturients undergoing elective cesarean section under combined spinal-epidural anesthesia, with singleton full-term pregnancy and aged 22-35 years, were enrolled from July to December 2025 at Jiangning Hospital Affiliated to Nanjing Medical University. Using a random number table, participants were allocated to two groups based on PCIA formulation: the sufentanil group (Group S) received sufentanil (3 μg/kg) + tropisetron (0.1 mg/kg) diluted to 150 mL with normal saline; the hydromorphone group (Group H) received hydromorphone (0.15 mg/kg) + tropisetron (0.1 mg/kg) diluted to 150 mL with normal saline. The primary outcome was the incidence of PPD at 6 weeks postoperatively. Secondary outcomes included PPD incidence at 1 week, Ramsay sedation scores at 24 and 48 h, Pittsburgh Sleep Quality Index (PSQI) scores preoperatively and at 24/48 h, resting Visual Analog Scale (VAS) pain scores at 6, 12, 24, and 48 h, PCIA button presses and rescue analgesia within 48 h, cumulative 48-hour opioid consumption, bowel function recovery time, first lactation time, neonatal behavioral neurological assessment (NBNA) scores at 48 h postoperatively and adverse reactions.
RESULTS: The incidence of PPD at 6 weeks was significantly lower in Group H compared to Group S [5.8% vs. 20.6%, relative risk (RR) = 0.28, 95% confidence interval (CI) 0.10 to 0.78, P = 0.004]. The absolute risk reduction was 14.8% (95% CI 4.2%-25.4%), corresponding to a number needed to treat (NNT) of 7 (95% CI 4-24). Ramsay and PSQI scores at 24 and 48 h were also significantly lower in Group H (P < 0.01 for all), as was the incidence of dizziness and drowsiness within 48 h (P < 0.01). No significant intergroup differences were found in analgesia-related outcomes or other adverse reactions.
CONCLUSION: Hydromorphone for PCIA after cesarean section can reduce the incidence of PPD at 6 weeks, improve early postoperative sleep quality, and decrease dizziness and drowsiness.
CLINICAL TRIAL REGISTRATION: https://www.chictr.org.cn/bin/home, identifier ChiCTR2500105264.